甲磺酸阿帕替尼治疗复发转移性乳腺癌的临床观察

曾会会; 胡婷; 王俊斌; 王明喜; 汪子书; 周阳阳

doi:10.13898/j.cnki.issn.1000-2200.2020.05.014

甲磺酸阿帕替尼治疗复发转移性乳腺癌的临床观察

The clinical efficacy of apatinib mesylate in the treatment of recurrent metastatic breast cancer

摘要

摘要:
目的探讨晚期复发转移性乳腺癌病人口服甲磺酸阿帕替尼的有效率和不良反应。
方法回顾性分析25例经3线治疗失败以上的晚期复发转移性乳腺癌病人临床资料，给予口服甲磺酸阿帕替尼，分析其客观有效率、疾病控制率、无进展生存期、总生存期及不良反应。
结果25例病人中，病情稳定11例，部分缓解4例，疾病进展10例，客观有效率16.0%，疾病控制率60.0%，中位无进展生存期3.68个月，总生存期16.06个月。多因素分析显示，既往化疗数和雌激素受体状态均为乳腺癌病人无进展生存期的影响因素（P < 0.05）。病人服用阿帕替尼主要不良反应为高血压（20.0%）、乏力（20.0%）、手足综合征（16.0%）和腹泻（16.0%），25例病人中无一例严重不良反应。
结论晚期复发转移性乳腺癌病人口服甲磺酸阿帕替尼获益率较高，不良反应可控，生活质量有所提高，值得进一步研究。

Abstract:
ObjectiveTo investigate the efficacy and safety of apatinib mesylate in the treatment of advanced recurrent metastatic breast cancer.
MethodsThe clinical data of 25 advanced recurrent metastatic breast cancer patients with more than 3-line treatment failure were retrospectively analyzed.The objective response rate, disease control rate, progress free survival, overall survival and safety in patients treated with oral apatinib mesylate were evaluated.
ResultsAmong 25 patients, the disease stabliation in 11 cases, partial remission in 4 cases and disease progression in 10 cases were identified.The objective response rate, disease control rate, median progress free survival and overall survival were 16.0%, 60.0%, 3.68 months and 16.06 months, respectively.The results of multi-factor analysis showed that the number of chemotherapy and ER status were the influencing factors of progress free survival(P < 0.05).The hypertension, fatigue, hand-foot syndrome and diarrhea were the main adverse reactions of apatinib, and no serious adverse reactions in 25 patients were found.
ConclusionThe apatinib mesylate in the treatment of advanced recurrent metastatic breast cancer has high efficacy, the adverse reactions is controllable, and the quality of life of patients can be improved, which is worthy of further study.

HTML全文

参考文献(14)

施引文献

资源附件(0)